{"id":"mycophenolic-acid-oral-product","safety":{"commonSideEffects":[{"rate":"20-25","effect":"Diarrhea"},{"rate":"15-20","effect":"Leukopenia"},{"rate":"10-15","effect":"Anemia"},{"rate":"15-20","effect":"Infection"},{"rate":"10-15","effect":"Nausea"},{"rate":"5-10","effect":"Vomiting"},{"rate":"10-15","effect":"Abdominal pain"},{"rate":"10-15","effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL866","moleculeType":"Small molecule","molecularWeight":"320.34"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Mycophenolic acid is a non-competitive, selective inhibitor of IMPDH type II, the enzyme responsible for guanosine nucleotide synthesis in lymphocytes. By depleting guanosine nucleotides, it preferentially inhibits T and B cell proliferation while sparing other cell types, resulting in immunosuppression. This mechanism makes it effective for preventing allograft rejection and treating autoimmune conditions.","oneSentence":"Mycophenolic acid inhibits inosine monophosphate dehydrogenase (IMPDH), selectively suppressing T and B lymphocyte proliferation to prevent organ rejection and autoimmune disease.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:56:14.950Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of organ rejection in renal transplant recipients"},{"name":"Prevention of organ rejection in cardiac transplant recipients"},{"name":"Prevention of organ rejection in hepatic transplant recipients"},{"name":"Lupus nephritis"}]},"trialDetails":[{"nctId":"NCT05436418","phase":"PHASE1, PHASE2","title":"The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-11-18","conditions":"Peripheral Blood Stem Cell Transplantation, Hematopoietic Stem Cell Transplantation","enrollment":260},{"nctId":"NCT06859424","phase":"PHASE2","title":"A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation","status":"RECRUITING","sponsor":"Center for International Blood and Marrow Transplant Research","startDate":"2025-07-25","conditions":"AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), Acute Leukemia (Category)","enrollment":358},{"nctId":"NCT07340463","phase":"PHASE2","title":"The Efficacy and Safety of Biologics (Belimumab/ Telitacicept) Induction Therapy in Proliferative Lupus Nephritis Patients for 6 Months Compared With Mycophenolate Mofetil Treatment","status":"RECRUITING","sponsor":"Nanjing University School of Medicine","startDate":"2025-12-08","conditions":"Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN)","enrollment":50},{"nctId":"NCT03249831","phase":"PHASE1","title":"A Blood Stem Cell Transplant for Sickle Cell Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2019-01-04","conditions":"Sickle Cell Disease, Sickle Cell Disorder, Hemoglobinopathies","enrollment":3},{"nctId":"NCT05156710","phase":"PHASE2","title":"BIVV020 (SAR445088) in Prevention and Treatment of Antibody-mediated Rejection (AMR)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2022-06-09","conditions":"Transplant Rejection","enrollment":48},{"nctId":"NCT03504241","phase":"PHASE1","title":"Tolerance by Engaging Antigen During Cellular Homeostasis","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2018-07-30","conditions":"Kidney Transplantation, Renal Transplantation, Renal Transplant Recipient","enrollment":8},{"nctId":"NCT05327023","phase":"PHASE1, PHASE2","title":"Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-05-23","conditions":"Hematologic Neoplasms","enrollment":430},{"nctId":"NCT03292861","phase":"PHASE2","title":"The Effect and Safety Profile of Thymoglobulin® in Primary Cardiac Transplant Recipients","status":"ENROLLING_BY_INVITATION","sponsor":"Cedars-Sinai Medical Center","startDate":"2018-09-13","conditions":"Heart Transplantation","enrollment":60},{"nctId":"NCT03922724","phase":"PHASE2","title":"Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-04-18","conditions":"Peripheral T-cell Lymphomas, Lymphoproliferative Disorders, Immune System Diseases","enrollment":330},{"nctId":"NCT06682169","phase":"PHASE3","title":"Evaluation of Rovadicitinib Compared to the Protocol Selected by Researchers in Third Line and Subsequent Studies of Moderate to Severe Chronic Graft-versus-host Disease","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2024-11-20","conditions":"Graft-versus-host Disease","enrollment":182},{"nctId":"NCT05806749","phase":"PHASE1","title":"Immunological Tolerance in Patients With Mismatched Kidney Transplants","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of California, Los Angeles","startDate":"2023-07-07","conditions":"End Stage Kidney Disease, Immunological Tolerance, Kidney Transplant Failure and Rejection","enrollment":16},{"nctId":"NCT04702256","phase":"PHASE3","title":"Induction Therapy for Lupus Nephritis With no Added Oral Steroids: A Trial Comparing Oral Corticosteroids Plus Mycophenolate Mofetil (MMF) Versus Obinutuzumab and MMF","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2021-12-09","conditions":"Lupus Nephritis, Systemic Lupus Erythematosus (SLE)","enrollment":196},{"nctId":"NCT02630628","phase":"PHASE3","title":"Efficacy and Safety of Tacrolimus Versus Mycophenolate in Lupus Nephritis","status":"COMPLETED","sponsor":"The University of Hong Kong","startDate":"2015-12-05","conditions":"Lupus Nephritis","enrollment":130},{"nctId":"NCT07053891","phase":"","title":"LUPKYNIS Drug-use Results Survey","status":"RECRUITING","sponsor":"Otsuka Pharmaceutical Co., Ltd.","startDate":"2025-09-17","conditions":"Lupus Nephritis","enrollment":400},{"nctId":"NCT00357565","phase":"PHASE2","title":"Hematopoietic Stem Cell Transplantation in the Treatment of Infant Leukemia","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2005-11","conditions":"Leukemia, Myelodysplastic Syndromes, Childhood Acute Myeloid Leukemia in Remission","enrollment":34},{"nctId":"NCT05237323","phase":"PHASE3","title":"Micophenolate Mofetil Versus Azathioprine in Myocarditis","status":"COMPLETED","sponsor":"I.M. Sechenov First Moscow State Medical University","startDate":"2020-10-01","conditions":"Lymphocytic Myocarditis (Disorder), Heart Failure, Dilated Cardiomyopathy","enrollment":50},{"nctId":"NCT06676384","phase":"PHASE4","title":"Which of the Commonly Available and Approved Drugs in Addition to Standard of Care Can Significantly Improve the Slope of Estimated Glomerular Filtration Rate at Two Years When Compared to Standard of Care Alone in South-Asian Kidney Biopsy-proven Adult (≥18 Years) Primary IgA Nephropathy?","status":"RECRUITING","sponsor":"Christian Medical College, Vellore, India","startDate":"2025-02-15","conditions":"IgA Nephropathy, Renal Insufficiency, Chronic, IgA Vasculitis","enrollment":585},{"nctId":"NCT02722668","phase":"PHASE2","title":"UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2017-05-15","conditions":"Acute Leukemia, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia/Lymphoma","enrollment":15},{"nctId":"NCT04477200","phase":"PHASE1","title":"Mycophenolate Mofetil Combined With Radiation Therapy in Glioblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2020-08-05","conditions":"Recurrent Glioblastoma, Recurrent Gliosarcoma, Recurrent Astrocytoma, Grade IV","enrollment":68},{"nctId":"NCT06412497","phase":"PHASE2","title":"MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.","status":"RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2024-06-05","conditions":"Severe Aplastic Anemia, Acquired Amegakaryocytic Thrombocytopenia, Acquired Pure Red Cell Aplasia","enrollment":60},{"nctId":"NCT04547049","phase":"PHASE3","title":"A Study Comparing Haploidentical Hematopoietic Stem Cell Transplantations (HSCTs) From Young Non-first-degree and Older First-degree Donors in Hematological Malignancies","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2020-09-01","conditions":"Leukemia","enrollment":176},{"nctId":"NCT06375005","phase":"PHASE2","title":"Efficacy and Safety of Telitacicept in the Treatment of Systemic Sclerosis","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-01-06","conditions":"Diffuse Cutaneous Systemic Sclerosis","enrollment":38},{"nctId":"NCT06758947","phase":"PHASE3","title":"Use of Selective JAK Inhibitor in ILD and Skin Tightness of Systemic Sclerosis Versus MMF","status":"COMPLETED","sponsor":"Assiut University","startDate":"2023-01-15","conditions":"Interstitial Lung Disease Due to Systemic Disease (Disorder)","enrollment":60},{"nctId":"NCT04660539","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of Satralizumab in Participants With Neuromyelitis Optica Spectrum Disorder (NMOSD)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2021-03-02","conditions":"Neuromyelitis Optica Spectrum Disorder","enrollment":119},{"nctId":"NCT03644485","phase":"PHASE4","title":"Clinical Outcome of Delayed or Standard Prograf Together With Induction Therapy Followed by Conversion to Advagraf in Donation After Cardiac (or Circulatory) Death (DCD) Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Astellas Pharma China, Inc.","startDate":"2018-10-21","conditions":"Kidney Transplant","enrollment":284},{"nctId":"NCT02991768","phase":"PHASE2","title":"Budesonide for Mycophenolic Acid-induced Diarrhea in Renal Transplant Recipients","status":"TERMINATED","sponsor":"University of Kansas Medical Center","startDate":"2017-01-27","conditions":"Diarrhea","enrollment":9},{"nctId":"NCT06557174","phase":"PHASE1, PHASE2","title":"A Study to Evaluate IMC-002 in Neuromyelitis Optica Spectrum Disorder (NMOSD) Patients","status":"NOT_YET_RECRUITING","sponsor":"ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd.","startDate":"2024-10-10","conditions":"Neuromyelitis Optica Spectrum Disorder (NMOSD)","enrollment":116},{"nctId":"NCT03955172","phase":"NA","title":"Efficiency of Everolimus for the Treatment of Kidney Transplanted Patients Presenting a Missing Self-induced NK-mediated Rejection","status":"RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2020-12-03","conditions":"Kidney Transplant Failure and Rejection","enrollment":20},{"nctId":"NCT03959241","phase":"PHASE3","title":"TAC/MTX vs. TAC/MMF/PTCY for Prevention of Graft-versus-Host Disease and Microbiome and Immune Reconstitution Study (BMT CTN 1703/1801)","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2019-06-25","conditions":"Acute Leukemia, Chronic Myelogenous Leukemia (CML), Myelodysplasia","enrollment":431},{"nctId":"NCT06044558","phase":"","title":"Effect of Azole/Echinocandin Use on Tacrolimus Pharmacokinetics","status":"COMPLETED","sponsor":"LI YAN","startDate":"2022-09-01","conditions":"Kidney Transplant Patients","enrollment":507},{"nctId":"NCT02661035","phase":"PHASE2","title":"Allo HSCT Using RIC for Hematological Diseases","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2017-03-09","conditions":"Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia","enrollment":156},{"nctId":"NCT00556933","phase":"PHASE4","title":"Improved Induction and Maintenance Immunosuppression in Kidney Transplantation","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2004-04-01","conditions":"End-stage Renal Disease","enrollment":180},{"nctId":"NCT00816413","phase":"PHASE1, PHASE2","title":"Donor Stem Cell Transplant, Pentostatin, and Total-Body Irradiation in Treating Patients With Hematological Cancer","status":"WITHDRAWN","sponsor":"University of Nebraska","startDate":"2008-09","conditions":"Chronic Myeloproliferative Disorders, Leukemia, Lymphoma","enrollment":""},{"nctId":"NCT01650545","phase":"PHASE1, PHASE2","title":"Aerosol Liposomal Cyclosporine for Chronic Rejection in Lung Transplant Recipients","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2012-07","conditions":"Disorder Related to Lung Transplantation, Bronchiolitis Obliterans, Decreased Immunologic Activity","enrollment":21},{"nctId":"NCT02028884","phase":"PHASE3","title":"Efficacy and Safety Study of Satralizumab (SA237) as Add-on Therapy to Treat Participants With Neuromyelitis Optica (NMO) and NMO Spectrum Disorder (NMOSD)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-02-20","conditions":"Neuromyelitis Optica (NMO), NMO Spectrum Disorder (NMOSD)","enrollment":85},{"nctId":"NCT05202145","phase":"PHASE1","title":"Drug-Drug Interaction (DDI) Study of ALXN2050 in Healthy Adult Participants","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2022-01-11","conditions":"Healthy","enrollment":61},{"nctId":"NCT01002742","phase":"PHASE3","title":"Acute Graft-versus-Host Disease Treatment (BMT CTN 0802)","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2010-01","conditions":"Graft-versus-Host Disease, Immune System Disorders","enrollment":236},{"nctId":"NCT04585152","phase":"PHASE2","title":"Rituximab Versus Mycophenolate Mofetil in Children With Steroid-dependent Idiopathic Nephrotic Syndrome.","status":"UNKNOWN","sponsor":"Istituto Giannina Gaslini","startDate":"2020-10-15","conditions":"Nephrotic Syndrome Steroid-Dependent","enrollment":160},{"nctId":"NCT05626387","phase":"PHASE4","title":"An RCT of Mycophenolate Mofetil (MMF) in Fibrotic Hypersensitivity Pneumonitis","status":"UNKNOWN","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2022-11-23","conditions":"Hypersensitivity Pneumonitis","enrollment":144},{"nctId":"NCT05221411","phase":"PHASE4","title":"Tacrolimus Versus Mycophenolate for Autoimmune Hepatitis Patients With Incomplete Response on First Line Therapy","status":"UNKNOWN","sponsor":"Leiden University Medical Center","startDate":"2022-01-19","conditions":"Autoimmune Hepatitis","enrollment":86},{"nctId":"NCT03108274","phase":"PHASE1","title":"A Drug Interaction Study Between Danicopan and Midazolam, Fexofenadine, and Mycophenolate Mofetil in Healthy Participants","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2017-04-18","conditions":"Healthy","enrollment":35},{"nctId":"NCT03582878","phase":"PHASE4","title":"Sirolimus vs Mycophenolate With Tacrolimus in Simultaneous Pancreas and Kidney Transplantation","status":"COMPLETED","sponsor":"Institute for Clinical and Experimental Medicine","startDate":"2004-01-01","conditions":"Diabetes Mellitus, Type 1","enrollment":238},{"nctId":"NCT01220856","phase":"PHASE2","title":"Reparixin in Pancreatic Islet Transplantation","status":"COMPLETED","sponsor":"Dompé Farmaceutici S.p.A","startDate":"2010-07-28","conditions":"Pancreatic Islet Transplantation in Type 1 Diabetes Mellitus","enrollment":9},{"nctId":"NCT02152345","phase":"PHASE4","title":"Belatacept Compared to Tacrolimus in Deceased Donor Renal Transplant Recipients","status":"COMPLETED","sponsor":"Columbia University","startDate":"2014-06","conditions":"Implant or Graft; Rejection","enrollment":57},{"nctId":"NCT02540395","phase":"NA","title":"Prospective Donor Specific T Response Measurment for IS Minimization in de Novo Renal Transplantation","status":"COMPLETED","sponsor":"Prof. Dr. Petra Reinke","startDate":"2015-03","conditions":"Disorder Related to Renal Transplantation, Effects of Immunosuppressant Therapy","enrollment":184},{"nctId":"NCT03262441","phase":"PHASE2","title":"MMF for HIV Reservoir Reduction","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2018-02-12","conditions":"Human Immunodeficiency Virus I Infection","enrollment":5},{"nctId":"NCT04402580","phase":"PHASE2","title":"Efficacy of Anti-CD20 Antibodies (Rituximab Biosimilar) in the Treatment of Childhood Steroid-dependent Nephrotic Syndrome","status":"TERMINATED","sponsor":"Istituto Giannina Gaslini","startDate":"2019-07-01","conditions":"Nephrotic Syndrome Steroid-Dependent","enrollment":30},{"nctId":"NCT03828682","phase":"PHASE4","title":"Veloxis de Novo Kidney Transplant ECSWD","status":"UNKNOWN","sponsor":"Simon Tremblay, PharmD, PhD","startDate":"2019-06-21","conditions":"Kidney Transplantation, Immunosuppression","enrollment":60},{"nctId":"NCT00657059","phase":"PHASE3","title":"Mycophenolate Mofetil (MMF) in Patients With IgA Nephropathy (IgAN)","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2007-09","conditions":"IgA Nephropathy","enrollment":151},{"nctId":"NCT00568633","phase":"PHASE3","title":"Allogeneic HCT Using Nonmyeloablative Host Conditioning With TLI & ATG vs SOC in AML","status":"TERMINATED","sponsor":"Stanford University","startDate":"2007-08","conditions":"Leukemia, Myeloid, Leukemia, Acute Myeloid Leukemia (AML)","enrollment":58},{"nctId":"NCT02077556","phase":"PHASE4","title":"Effect of Everolimus on the Pharmacokinetics of Tacrolimus in Renal Transplant Patients","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2014-04","conditions":"Drug Interaction Potentiation","enrollment":14},{"nctId":"NCT00866879","phase":"PHASE4","title":"Randomized Conversion of Calcineurin-Inhibitors in Renal Allograft Recipients","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2007-06","conditions":"Renal Transplant Rejection","enrollment":275},{"nctId":"NCT02042690","phase":"PHASE3","title":"Haplo-identical HSCT Versus Chemotherapy for Adult Acute Lymphoblastic Leukemia Patients","status":"COMPLETED","sponsor":"Peking University","startDate":"2014-07","conditions":"Acute Lymphoblastic Leukemia","enrollment":131},{"nctId":"NCT00489281","phase":"PHASE2","title":"Non-Myeloablative Bone Marrow Transplant for Patients With Sickle Cell Anemia and Other Blood Disorders","status":"TERMINATED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2008-06-23","conditions":"Sickle Cell Disease","enrollment":43},{"nctId":"NCT02129881","phase":"PHASE1, PHASE2","title":"The ONE Study UK Treg Trial","status":"COMPLETED","sponsor":"Guy's and St Thomas' NHS Foundation Trust","startDate":"2014-04","conditions":"End-stage Renal Failure","enrollment":15},{"nctId":"NCT01093885","phase":"NA","title":"Study of Ambrisentan With Antifibrotic Agent Combination Therapy in Diffuse Systemic Sclerosis","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2010-02","conditions":"Systemic Sclerosis, Scleroderma","enrollment":15},{"nctId":"NCT00991510","phase":"PHASE4","title":"Comparative Bioavailability of Myfenax® and CellCept® in Kidney Transplant Patients","status":"TERMINATED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2009-08","conditions":"Stable Renal Transplant Recipients","enrollment":43},{"nctId":"NCT01433978","phase":"PHASE3","title":"A Phase 3, Multicenter, Randomized, Double-blind,Active-controlled, Parallel-group Trial With an Open-labelExtension Phase to Evaluate the Efficacy and Safety of OralE5501 Versus Eltrombopag, in Adults With Chronic ImmuneThrombocytopenia (Idiopathic Thrombocytopenic Purpura)","status":"TERMINATED","sponsor":"Eisai Inc.","startDate":"2012-03-26","conditions":"Idiopathic Thrombocytopenic Purpura","enrollment":24},{"nctId":"NCT01438840","phase":"PHASE3","title":"Efficacy and Safety of Oral E5501 Plus Standard of Care for the Treatment of Thrombocytopenia in Adults With Chronic Immune Thrombocytopenia (Amendment 02)","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2012-02-16","conditions":"Chronic Thrombocytopenia, Immune Thrombocytopenia","enrollment":49},{"nctId":"NCT00354172","phase":"PHASE2","title":"Donor Umbilical Cord Blood Natural Killer Cells, Aldesleukin and Umbilical Cord Blood Transplant in Patients With Refractory Hematologic Cancers.","status":"TERMINATED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2006-02","conditions":"Leukemia, Myelodysplastic Syndromes","enrollment":16},{"nctId":"NCT00686556","phase":"PHASE1","title":"Total Marrow Irradiation for Refractory Acute Leukemia","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2012-08","conditions":"Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, Multiple Myeloma","enrollment":12},{"nctId":"NCT00186628","phase":"PHASE2","title":"Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD","status":"COMPLETED","sponsor":"Stanford University","startDate":"2005-06","conditions":"Leukemia, Mast-Cell, Mantle-cell Lymphoma","enrollment":36},{"nctId":"NCT00899847","phase":"PHASE2","title":"Phase 2 Study of Autologous Followed by Nonmyeloablative Allogeneic Transplantation Using TLI & ATG","status":"COMPLETED","sponsor":"Stanford University","startDate":"2009-05","conditions":"Transplantation, Homologous, Transplantation, Autologous, Multiple Myeloma","enrollment":9},{"nctId":"NCT00281879","phase":"PHASE2","title":"Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer","status":"TERMINATED","sponsor":"OHSU Knight Cancer Institute","startDate":"2006-02","conditions":"Chronic Myeloproliferative Disorders, Leukemia, Lymphoma","enrollment":200},{"nctId":"NCT01998789","phase":"PHASE2","title":"Everolimus Post Orthotopic Liver Transplant","status":"UNKNOWN","sponsor":"Tomoaki Kato","startDate":"2013-10","conditions":"Orthotopic Liver Transplant","enrollment":50},{"nctId":"NCT00639717","phase":"PHASE2","title":"Addition of Etanercept and Extracorporeal Photopheresis (ECP) to Standard Graft-Versus-Host Disease (GVHD) Prophylaxis in Stem Cell Transplant","status":"COMPLETED","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2009-03","conditions":"Graft Versus Host Disease","enrollment":48},{"nctId":"NCT01220297","phase":"PHASE2","title":"Sirolimus & Mycophenolate Mofetil as GvHD Prophylaxis in Myeloablative, Matched Related Donor HCT","status":"TERMINATED","sponsor":"Stanford University","startDate":"2006-08","conditions":"Hematologic Diseases, Acute-graft-versus-host Disease, Leukemia","enrollment":3},{"nctId":"NCT00596947","phase":"PHASE4","title":"Prednisone Withdrawal Versus Prednisone Maintenance After Kidney Transplant","status":"TERMINATED","sponsor":"University of Pennsylvania","startDate":"2005-10","conditions":"Transplants and Implants","enrollment":18},{"nctId":"NCT00883129","phase":"PHASE2","title":"Comparison of Therapeutic Regimens for Scleroderma Interstitial Lung Disease (The Scleroderma Lung Study II)","status":"COMPLETED","sponsor":"Michael Roth","startDate":"2009-09","conditions":"Scleroderma, Interstitial Lung Disease","enrollment":142},{"nctId":"NCT00141037","phase":"PHASE1, PHASE2","title":"Steroid-Free Versus Steroid-Based Immunosuppression in Pediatric Renal (Kidney) Transplantation","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2004-03","conditions":"Kidney Diseases, Kidney Transplantation, Kidney Transplant","enrollment":130},{"nctId":"NCT00023231","phase":"NA","title":"Pediatric Kidney Transplant Without Calcineurin Inhibitors","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2001-02","conditions":"End-Stage Renal Disease","enrollment":35},{"nctId":"NCT02630563","phase":"PHASE2","title":"Safety, Tolerability and Pharmacokinetics of Oral CellCept (Mycophenolate Mofetil) in Pediatric Liver Transplant Recipients on Concomitant Treatment With Cyclosporine and Corticosteroids","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2003-05","conditions":"Pediatric Liver Transplantation","enrollment":9},{"nctId":"NCT01187953","phase":"PHASE3","title":"Double-Blind,Double-Dummy,Efficacy/Safety,LCP-Tacro™ Vs Prograf®,Prevention Rejection,De Novo Adult Kidney Tx","status":"COMPLETED","sponsor":"Veloxis Pharmaceuticals","startDate":"2010-09","conditions":"Renal Failure","enrollment":543},{"nctId":"NCT02339441","phase":"","title":"Treatment Outcome in Early Diffuse Cutaneous Systemic Sclerosis","status":"COMPLETED","sponsor":"University of Manchester","startDate":"2010-06","conditions":"Early Diffuse Cutaneous Systemic Sclerosis","enrollment":320},{"nctId":"NCT00423826","phase":"","title":"Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease","status":"NO_LONGER_AVAILABLE","sponsor":"Barbara Ann Karmanos Cancer Institute","startDate":"2007-01","conditions":"Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm","enrollment":""},{"nctId":"NCT02686619","phase":"PHASE3","title":"Study Comparing Efficacy and Safety of Mycophenolate Mofetil (Cellcept) With Delayed Introduction of Sirolimus and Discontinuation of Cyclosporine, With Those of Mycophenolate Mofetil and Long Term Continuation of Cyclosporine in Renal Transplant Recipients","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2004-11","conditions":"Renal Transplantation","enrollment":237},{"nctId":"NCT00717678","phase":"PHASE3","title":"A Randomized Study to Assess the Safety and Efficacy of Prograf vs Prograf-XL in de Novo Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2007-12","conditions":"Kidney Transplantation, Transplantation Immunology, Host vs Graft Reaction","enrollment":73},{"nctId":"NCT01109914","phase":"PHASE4","title":"Mucosal Response in Immunocompromised Host","status":"COMPLETED","sponsor":"Leiden University Medical Center","startDate":"2010-04","conditions":"Kidney Transplantation, Immunity","enrollment":51},{"nctId":"NCT01435291","phase":"PHASE4","title":"AADAPT - Analysis of Advagraf Dose Adaptation Post Transplantation","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nice","startDate":"2011-10","conditions":"Renal Transplantation","enrollment":45},{"nctId":"NCT01596062","phase":"PHASE2","title":"Pharmacodynamics, Efficacy and Safety of Basiliximab 40 or 80 mg in Combination With Ciclosporine Microemulsion or Everolimus, in Adult Low Risk de Novo Renal Transplant Recipients (IDEALE Study)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-03","conditions":"Renal Transplantation","enrollment":16},{"nctId":"NCT00545402","phase":"PHASE4","title":"A Study of CellCept (Mycophenolate Mofetil) in Combination Therapy in Liver Transplant Patients.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2007-11","conditions":"Liver Transplantation","enrollment":180},{"nctId":"NCT00810602","phase":"PHASE1, PHASE2","title":"Vorinostat to Prevent Graft Versus Host Disease Following Reduced Intensity, Related Donor Stem Cell Transplant","status":"COMPLETED","sponsor":"Pavan Reddy, MD","startDate":"2009-01","conditions":"Hematologic Malignancies, Graft vs Host Disease","enrollment":61},{"nctId":"NCT02075242","phase":"PHASE4","title":"TO Compare the Triple Drug Therapy and Dual Therapy .","status":"UNKNOWN","sponsor":"Asan Medical Center","startDate":"2014-01","conditions":"HEPATITIS","enrollment":170},{"nctId":"NCT00035555","phase":"PHASE2","title":"Study Comparing the Safety and Efficacy of Belatacept With That of Cyclosporine in Patients With a Transplanted Kidney","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2001-03","conditions":"Graft Rejection, Kidney Transplantation, Renal Transplantation","enrollment":230},{"nctId":"NCT00658320","phase":"PHASE3","title":"Concentration Controlled Everolimus With Reduced Dose Cyclosporine Versus Mycophenolate Mofetil With Standard Dose Cyclosporine in de Novo Renal Transplant Adult Recipients Treated With Basiliximab and Corticosteroids","status":"COMPLETED","sponsor":"Novartis","startDate":"2008-02","conditions":"Kidney Transplantation","enrollment":122},{"nctId":"NCT01609673","phase":"NA","title":"Study of Everolimus in de Novo Renal Transplant Recipients","status":"TERMINATED","sponsor":"Helady Pinheiro, MD, PhD","startDate":"2013-03","conditions":"End Stage Renal Failure With Renal Transplant","enrollment":1},{"nctId":"NCT01154387","phase":"PHASE1, PHASE2","title":"Evaluating Safety and Efficacy of TOL101 Induction Versus Anti-Thymocyte Globulin to Prevent Kidney Transplant Rejection","status":"UNKNOWN","sponsor":"Tolera Therapeutics, Inc","startDate":"2010-07","conditions":"End Stage Renal Disease, Renal Transplant","enrollment":85},{"nctId":"NCT00768729","phase":"PHASE1","title":"Safety of Immunosuppression Minimization in Children and Adolescents After Kidney Transplantation","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2009-05","conditions":"Kidney Failure, Chronic, Kidney Transplantation, Immunosuppression","enrollment":7},{"nctId":"NCT00296244","phase":"PHASE4","title":"Steroid Free Immunosuppression in Liver Transplantation","status":"COMPLETED","sponsor":"Thomas Jefferson University","startDate":"2006-02","conditions":"Liver Cirrhosis, Liver Transplant Disorder","enrollment":40},{"nctId":"NCT00183248","phase":"PHASE1, PHASE2","title":"Using Donor Stem Cells and Alemtuzumab to Prevent Organ Rejection in Kidney Transplant Patients","status":"COMPLETED","sponsor":"University of Miami","startDate":"2004-09","conditions":"Kidney Transplantation, Kidney Disease, Kidney Failure","enrollment":9},{"nctId":"NCT01596075","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of Cannabidiol for Grade I/II Acute Graft Versus Host Disease (GVHD) After Allogeneic Stem Cell Transplantation","status":"UNKNOWN","sponsor":"Rabin Medical Center","startDate":"2012-07","conditions":"Graft Versus Host Disease","enrollment":40},{"nctId":"NCT00316810","phase":"PHASE3","title":"Simultaneous Pancreas-kidney Transplantation With Campath Protocol","status":"COMPLETED","sponsor":"Dr. Claudia Bösmüller","startDate":"2006-04","conditions":"Pancreas-Kidney Transplantation","enrollment":30},{"nctId":"NCT01446484","phase":"PHASE1, PHASE2","title":"Treatment of Children With Kidney Transplants by Injection of CD4+CD25+FoxP3+ T Cells to Prevent Organ Rejection","status":"UNKNOWN","sponsor":"Pirogov Russian National Research Medical University","startDate":"2011-10","conditions":"End-Stage Renal Disease, Kidney Failure","enrollment":30},{"nctId":"NCT00187915","phase":"NA","title":"Pilot Trial for Implementation of a MPA PK Monitoring Strategy","status":"COMPLETED","sponsor":"University of Florida","startDate":"2003-07","conditions":"Transplant, Kidney","enrollment":24},{"nctId":"NCT01364987","phase":"PHASE1","title":"Pharmacokinetic Interaction Study to Assess the Effect of ASP015K on Mycophenolate Mofetil in Healthy Volunteers","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2009-05","conditions":"Healthy Subjects, Drug Interactions, Pharmacokinetics of ASP015K","enrollment":24},{"nctId":"NCT00975663","phase":"PHASE4","title":"Bayesian Dose Adjustment of Immunosuppressants After Lung Transplantation","status":"TERMINATED","sponsor":"University Hospital, Limoges","startDate":"2009-09","conditions":"Lung and Heart-lung Transplantation","enrollment":180},{"nctId":"NCT01080443","phase":"NA","title":"Bioequivalence Study of Mycophenolate Mofetil 250 mg Capsule Under Fasting Condition","status":"COMPLETED","sponsor":"Panacea Biotec Ltd","startDate":"2008-06","conditions":"Healthy Volunteers","enrollment":56},{"nctId":"NCT01080417","phase":"NA","title":"Bioequivalence Study of Mycophenolate Mofetil 250 mg Capsule Under Fed Condition","status":"COMPLETED","sponsor":"Panacea Biotec Ltd","startDate":"2008-06","conditions":"Healthy Volunteers","enrollment":84},{"nctId":"NCT00720408","phase":"PHASE3","title":"A Randomized Study to Assess the Safety and Efficacy of Prograf vs Prograf-XL in de Novo Liver Transplant Recipients.","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2007-12","conditions":"Liver Transplantation, Transplantation Immunology, Host vs Graft Reaction","enrollment":48},{"nctId":"NCT00166244","phase":"PHASE4","title":"Fixed Dose MMF vs Concentration Controlled MMF After Renal Transplantation","status":"COMPLETED","sponsor":"Erasmus Medical Center","startDate":"2003-05","conditions":"De Novo Renal Transplant Recipient.","enrollment":901}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Myfortic","MPA"],"phase":"marketed","status":"active","brandName":"Mycophenolic Acid Oral Product","genericName":"Mycophenolic Acid Oral Product","companyName":"Simon Tremblay, PharmD, PhD","companyId":"simon-tremblay-pharmd-phd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Mycophenolic acid inhibits inosine monophosphate dehydrogenase (IMPDH), selectively suppressing T and B lymphocyte proliferation to prevent organ rejection and autoimmune responses. Used for Prevention of organ rejection in renal transplant recipients, Prevention of organ rejection in cardiac transplant recipients, Prevention of organ rejection in hepatic transplant recipients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}